{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T03:45:23Z","timestamp":1774669523105,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s11886-021-01559-3","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T14:04:07Z","timestamp":1629122647000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Commentary on the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in CKD"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3154-5332","authenticated-orcid":false,"given":"Johannes F. E.","family":"Mann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara I.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C.","family":"Cushman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan L.","family":"Furth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim H.","family":"Ix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan Fan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A.","family":"Knoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Muntner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Pecoits-Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Sarnak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles R. V.","family":"Tomson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan C.","family":"Craig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Tunnicliffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Howell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Tonelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Earley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred K.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"key":"1559_CR1","unstructured":"Kidney Disease: Improving Global Outcomes Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99:S1\u2013S87. This guideline updates the previous 2012 edition and is accompanied by an Executive Summary which offers a quick overview of the key takeaways from this guidance document."},{"key":"1559_CR2","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:e127\u2013248.","journal-title":"J Am Coll Cardiol"},{"key":"1559_CR3","doi-asserted-by":"crossref","unstructured":"Agarwal R. Implications of blood pressure measurement technique for implementation of Systolic Blood Pressure Intervention Trial (SPRINT). J Am Heart Assoc. 2017;6:e004536. This key paper demonstrated that in individuals with CKD, there is a wide variability in terms of BP measured \u201croutinely\u201d vs. by standardized technique, and that these differences are unpredictable in any given individual.","DOI":"10.1161\/JAHA.116.004536"},{"key":"1559_CR4","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1161\/HYPERTENSIONAHA.117.10479","volume":"71","author":"KC Johnson","year":"2018","unstructured":"Johnson KC, Whelton PK, Cushman WC, et al. Blood pressure measurement in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension. 2018;71:848\u201357.","journal-title":"Hypertension"},{"key":"1559_CR5","doi-asserted-by":"crossref","unstructured":"Uhlig K, Patel K, Ip S, et al. Self-measured blood pressure monitoring in the management of hypertension: a systematic review and meta-analysis. Ann Intern Med. 2013;159:185\u201394. This report provides a detailed analysis of the main 3 trials up to 2012 that examined target BP in people with high BP and CKD, with kidney disease progression as main outcome. The arrival of SPRINT-CKD trial after this publication has furnished additional CV outcome data which provided the impetus for this guideline update.","DOI":"10.7326\/0003-4819-159-3-201308060-00008"},{"key":"1559_CR6","unstructured":"World Health Organization. Guideline: Sodium Intake for Adults and Children. Available at: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/77985\/9789241504836_eng.pdf?sequence\u00bc1; 2012. Accessed January 15, 2021."},{"key":"1559_CR7","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","volume":"98","author":"Kidney Disease: Improving Global Outcomes Diabetes Work Group","year":"2020","unstructured":"Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98:S1\u2013S115.","journal-title":"Kidney Int"},{"key":"1559_CR8","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36:1953\u20132041.","journal-title":"J Hypertens"},{"key":"1559_CR9","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cjca.2020.02.086","volume":"36","author":"DM Rabi","year":"2020","unstructured":"Rabi DM, McBrien KA, Sapir-Pichhadze R, et al. Hypertension Canada\u2019s 2020 Comprehensive Guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Can J Cardiol. 2020;36:596\u2013624.","journal-title":"Can J Cardiol"},{"key":"1559_CR10","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103\u201316.","journal-title":"N Engl J Med"},{"key":"1559_CR11","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJM199403313301301","volume":"330","author":"S Klahr","year":"1994","unstructured":"Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994;330:877\u201384.","journal-title":"N Engl J Med"},{"key":"1559_CR12","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","volume":"288","author":"JT Wright Jr","year":"2002","unstructured":"Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421\u201331.","journal-title":"JAMA"},{"key":"1559_CR13","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(05)71082-5","volume":"365","author":"P Ruggenenti","year":"2005","unstructured":"Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365:939\u201346.","journal-title":"Lancet"},{"key":"1559_CR14","unstructured":"Bress AP, King JB, Kreider KE, et al. Effect of intensive versus standard blood pressure treatment according to baseline prediabetes status: a post hoc analysis of a randomized trial. Diabetes Care. 2017;40:1401\u20138. The results from this SPRINT post hoc analysis demonstrated similar benefits in those with intensive SBP treatment among those with prediabetes and fasting normoglycemia."},{"key":"1559_CR15","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"WC Cushman","year":"2010","unstructured":"ACCORD Study Group, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575\u201385.","journal-title":"N Engl J Med"},{"key":"1559_CR16","unstructured":"Beddhu S, Chertow GM, Greene T, et al. Effects of intensive systolic blood pressure lowering on cardiovascular events and mortality in patients with type 2 diabetes mellitus on standard glycemic control and in those without diabetes mellitus: reconciling results from ACCORD BP and SPRINT. J Am Heart Assoc. 2018;7:e009326 The results of intensive SBP control on cardiovascular disease events and all-cause mortality appear to vary depending on the intensity of glycemic control."},{"key":"1559_CR17","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(13)60852-1","volume":"382","author":"OR Benavente","year":"2013","unstructured":"S.P.S. Study Group, Benavente OR, Coffey CS, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382:507\u201315.","journal-title":"Lancet"},{"key":"1559_CR18","unstructured":"National Institute for Health and Care Excellence: hypertension in adults: diagnosis and management. NICE guideline [NG136]. Available at: https:\/\/www.nice.org.uk\/guidance\/ng136; 2019. Accessed January 15, 2021."},{"key":"1559_CR19","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","volume":"67","author":"X Xie","year":"2016","unstructured":"Xie X, Liu Y, Perkovic V, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016;67:728\u201341.","journal-title":"Am J Kidney Dis"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-021-01559-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-021-01559-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-021-01559-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T09:43:37Z","timestamp":1744191817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-021-01559-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1559"],"URL":"https:\/\/doi.org\/10.1007\/s11886-021-01559-3","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]},"assertion":[{"value":"30 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tara I. Chang, MD, MS: consultancy: Janssen; Novo Nordisk; grants\/grants pending: Satellite Health Care*, National Institutes of Health, American Heart Association; workshop honoraria: Fresenius.Alfred K. Cheung, MD: consultancy: Boehringer Ingelheim; grants\/grants pending: National Institutes of Health for SPRINT.William C. Cushman, MD: consultancy: Sanofi; grants\/grants pending: National Institute on Aging*; National Institutes of Health*; and Eli Lilly*.Susan L. Furth, MD, PhD: grants\/grants pending: National Institutes of Health*.Joachim H. Ix, MD, MAS: grants\/grants pending: Baxter International*; National Institutes of Diabetes and Digestive and Kidney Diseases*; and American Heart Association*; travel expenses: American Society of Nephrology and Institute of Medicine.Fan Fan Hou, MD, PhD: consultancy: AbbVie and AstraZeneca; grants\/grants pending: National Natural Science Foundation of China; Ministry of Science and Technology of China.Gregory A. Knoll, MD, MSc, FRCPC: grants\/grants pending: Canadian Institutes of Health Research*.Johannes F.E. Mann, MD: consultancy: AstraZeneca; Bayer Healthcare; Boehringer Ingelheim; Fresenius Medical Care; Novo Nordisk; and Vifor Pharma; grants\/grants pending: AbbVie; Boehringer Ingelheim; Canadian Institutes Health Research; Celgene; European Union; Idorsia; Novo Nordisk; Roche; Sanofi; and Sandoz; Speaker Bureaus: Amgen; AstraZeneca; Braun; Fresenius Medical Care; Gambro; Medice; Novo Nordisk; Roche.Paul Muntner, PhD MHS, FASH, FAHA: noneRoberto Pecoits-Filho, MD, PhD, FASN, FACP: consultancy: AstraZeneca; Akebia; Fresenius Medical Care; and Novo Nordisk; grants\/grants pending: Fresenius Medical Care*; Speaker Bureaus: AstraZeneca and Novo Nordisk.Mark J. Sarnak, MD, MS: consultancy: Akebia*; grants\/grants pending: National Institutes of Health*.Sheldon W. Tobe, MD, MScCH (HPTE): honorarium: CHEP+ a physician organization CPD not-for-profit organization that provides Canadian accredited continuing education. CHEP+ has received support in accordance with accreditation protocols from The University of Toronto, The Royal College of Physicians and Surgeons of Canada, Astra Zeneca, Bayer, Bristol Myers Squibb, Janssen, Pfizer.Charles R.V. Tomson, DM, FRCP: travel: Attendance at a London Hatter Institute meeting organized by the Lancet and University College London with arm\u2019s- length funding from pharmaceutical companies.The other authors declare that they have no conflict of interest.* monies to institution","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"132"}}